Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Patients with RA in the Setting of Cardiovascular Disease

  |  Issue: March 2025  |  

Samantha C. Shapiro, MDSamantha C. Shapiro, MD, is a clinician educator who is passionate about the care and education of rheumatology patients. She writes for both medical and lay audiences and practices telerheumatology.

References

  1. van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017 Apr;37(4):487–493. doi:10.1007/s00296-016-3638-5
  2. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303–1307. doi:10.1161/01.CIR.0000054612.26458.B2
  3. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum. 2005 Feb;52(2):412–420. doi:10.1002/art.20855
  4. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Sep;56(9):2905–2912. doi:10.1002/art.22809
  5. Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018 Jan;77(1): 48–54. doi:10.1136/annrheumdis-2017-211735
  6. Zhou D, Xi B, Zhao M, et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III linked mortality study. Sci Rep. 2018 Jun 20;8(1):9418. doi:10.1038/s41598-018-27377-2
  7. Roelsgaard IK, Ikdahl E, Rollefstad S, et al. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology (United Kingdom). 2020 Aug 1;59(8):1997–2004. doi:10.1093/rheumatology/kez557
  8. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: A scientific statement from the American Heart Association. Circulation. 2022 Mar;145(9):e722–e759. doi:10.1161/CIR.0000000000001040
  9. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326. doi:10.1056/nejmoa2109927
  10. Charles-Schoeman C, Buch MH, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023 Jan;82(1):119–129. doi:10.1136/ard-2022-222259
  11. Giles J, Charles-Schoeman C, Buch M, et al. Use of statins and its association with major adverse cardiovascular outcomes with tofacitinib versus TNF inhibitors in a risk-enriched population of patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9).

Related Articles

    Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

    Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

    Physical Activity, Exercise Can Benefit Patients with RA

    While medical advances in rheumatoid arthritis (RA) have led to improvements in disease control and quality of life for patients worldwide, the rate for stable remission remains low.1 Management of RA symptoms is traditionally accomplished through a combination of medications and nonpharmacological interventions.2 This approach can prevent the development of secondary adverse health outcomes. Two…